Insights

Loading spinner
Gathering insights about AFFiRiS AG

Similar companies to AFFiRiS AG

AFFiRiS AG Tech Stack

AFFiRiS AG uses 8 technology products and services including Cookie Notice, Shopify, jQuery, and more. Explore AFFiRiS AG's tech stack below.

  • Cookie Notice
    Cookie Compliance
  • Shopify
    E-commerce
  • jQuery
    Javascript Libraries
  • jQuery Migrate
    Javascript Libraries
  • Open Graph
    Miscellaneous
  • wpBakery
    Page Builders
  • Yoast SEO
    Search Engines
  • Apache
    Web Servers

AFFiRiS AG's Email Address Formats

AFFiRiS AG uses at least 1 format(s):
AFFiRiS AG Email FormatsExamplePercentage
First.Last@affiris.comJohn.Doe@affiris.com
50%
First.Last@affiris.comJohn.Doe@affiris.com
50%

Frequently Asked Questions

Where is AFFiRiS AG's headquarters located?

Minus sign iconPlus sign icon
AFFiRiS AG's main headquarters is located at Karl-Farkas-Gasse 22 Wien, 1030 AT. The company has employees across 2 continents, including EuropeNorth America.

What is AFFiRiS AG's phone number?

Minus sign iconPlus sign icon
You can contact AFFiRiS AG's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is AFFiRiS AG's official website and social media links?

Minus sign iconPlus sign icon
AFFiRiS AG's official website is affiris.com and has social profiles on LinkedIn.

What is AFFiRiS AG's SIC code NAICS code?

Minus sign iconPlus sign icon
AFFiRiS AG's SIC code is 6531 - Real Estate Agents and Managers NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does AFFiRiS AG have currently?

Minus sign iconPlus sign icon
As of February 2022, AFFiRiS AG has approximately 11 employees across 2 continents, including EuropeNorth America. Key team members include Head External Manufacturing: H. S.Ceo: N. B.Clinical Quality Assurance Manager: E. S.. Explore AFFiRiS AG's employee directory with LeadIQ.

What industry does AFFiRiS AG belong to?

Minus sign iconPlus sign icon
AFFiRiS AG operates in the Biotechnology Research industry.

What technology does AFFiRiS AG use?

Minus sign iconPlus sign icon
AFFiRiS AG's tech stack includes Cookie NoticeShopifyjQueryjQuery MigrateOpen GraphwpBakeryYoast SEOApache.

What is AFFiRiS AG's email format?

Minus sign iconPlus sign icon
AFFiRiS AG's email format typically follows the pattern of . Find more AFFiRiS AG email formats with LeadIQ.

How much funding has AFFiRiS AG raised to date?

Minus sign iconPlus sign icon
As of February 2022, AFFiRiS AG has raised $11M in funding. The last funding round occurred on Apr 25, 2017 for $11M.

When was AFFiRiS AG founded?

Minus sign iconPlus sign icon
AFFiRiS AG was founded in 2003.
AFFiRiS AG

AFFiRiS AG

Biotechnology ResearchWien, Austria11-50 Employees

We are a clinical-stage biotechnology company that strives to challenge established treatment options for neurodegenerative diseases in order to preserve the quality of life of patients.

WE FOCUS ON UNMET MEDICAL NEEDS IN CHRONIC DISEASES
Currently available treatments for many neurodegenerative diseases aim to manage symptoms, and do not stop disease progression. As a result, neurodegenerative diseases often lead to a reduced quality of life. Better treatments for these diseases are needed to give patients healthier, happier, and longer lives. We aim to develop therapeutic and preventative treatments that address the root causes of neurodegenerative diseases: an ethos inspired by the impact of vaccines on health and society worldwide.

OUR APPROACH
Our novel approach, Specific Active ImmunoTherapy (SAIT), stimulates the body’s own immune system to find and fight proteins central to the development and progression of neurodegenerative diseases. SAIT was developed using our AFFITOME technology, which allows for optimization of immune responses against pathogenic forms of proteins, and it may permit targeting of multiple pathogenic proteins in one disease setting. SAIT is designed to induce a long-lasting immune response, which we anticipate will translate into effective quarterly/twice-yearly dosing.

OUR PIPELINE
We have a broad portfolio of immunotherapy candidates, which are currently in clinical trials or preclinical development for chronic diseases, including Parkinson’s Disease, multiple system atrophy (MSA), dementia with Lewy bodies (DLB), and Huntington's disease.

OUR TEAM
We are a passionate and dedicated team with a proven track record of making ground-breaking scientific discoveries and developing novel therapies. Our exciting work spans early discovery, preclinical advancement of SAIT and monoclonal antibody drug candidates, and translation of science into clinical development.

Please follow us on LinkedIn and visit www.affiris.com.

Section iconCompany Overview

Headquarters
Karl-Farkas-Gasse 22 Wien, 1030 AT
Phone number
SIC Code
6531 - Real Estate Agents and Managers
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2003
Employees
11-50

Section iconFunding & Financials

  • $11M

    AFFiRiS AG has raised a total of $11M of funding over 4 rounds. Their latest funding round was raised on Apr 25, 2017 in the amount of $11M.

Section iconFunding & Financials

  • $11M

    AFFiRiS AG has raised a total of $11M of funding over 4 rounds. Their latest funding round was raised on Apr 25, 2017 in the amount of $11M.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.